To better understand what KBI-092 refers to, I would need more context or information about the specific research, clinical trials, or therapeutic areas related to this compound.
The "lock and key" specificity of KBI-092 is what gives it therapeutic promise. Unlike older drugs that might affect multiple systems in the body, leading to side effects, a compound like KBI-092 is likely engineered for high selectivity, aiming to strike a disease at its root while sparing healthy tissue. KBI-092
There is currently no widely recognized pharmaceutical compound or material officially designated as [1, 2]. It is possible this term refers to one of several similarly named investigational drugs or experimental series. To better understand what KBI-092 refers to, I
: It works by inhibiting AKT kinases (AKT1, AKT2, and AKT3), which are often overactive in cancer and certain genetic disorders. 2. BIIB092 (Gosuranemab) 2. BIIB092 (Gosuranemab)